Research Projects & Grants

For Profit Organization

• J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Investigator, Eli Lilly & Co., (06/2024 - 06/2025) Status: Approved
• A Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03), Role: Investigator, AstraZeneca Pharmaceuticals, L.P. (USA), (01/2024 - 01/2026) Status: Approved
• A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (02/2025 - 02/2026) Status: Approved

Internal

• Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy, Role: Investigator, LLU Dept. of Medicine, (04/2025 - 04/2026) Status: Approved